Aker BioMarine AS (AKBM.OL) Stock Analysis & AI Equity Report
Aker BioMarine AS (AKBM.OL) overview
Aker BioMarine AS (AKBM.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Aker BioMarine AS reported revenue of USD 199m and operating profit of USD -6.5m; the year-end share price was 67.10 NOK and market capitalisation was NOK 5,883m. Aker BioMarine AS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aker BioMarine AS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-01-29. Data will be refreshed during report generation.
About Aker BioMarine AS
Aker BioMarine develops krill-based and algae-based ingredients, supplements, and related nutrition products for human health. Its portfolio includes Superba Krill Oil, Revervia algae oil, Lysoveta, and other delivery and specialty nutrition platforms. The company has also been narrowing its focus toward human health after completing the sale of its feed ingredients business.
Generate the Aker BioMarine AS report
Aker BioMarine AS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Aker BioMarine AS and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.